Clinical Trials

Overview

About this study

The purpose of this study is to validate the real-world performance of our previously developed AI-ECG algorithm for identification of hyperkalemia with a six-lead mobile-enhanced device  

Ambulatory adult patients at increased risk for hyperkalemia due to age ≥ 50 years, and one or more criteria including eGFR (from serum creatinine) < 45 ml/minute and/or a history of serum potassium > 5.2 mEq/l, who present to the emergency department will be approached to consent for our rapid screening process.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Participating Mayo Clinic locations

More information